Compare DMRC & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DMRC | MDXH |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.6M | 149.0M |
| IPO Year | 2008 | 2021 |
| Metric | DMRC | MDXH |
|---|---|---|
| Price | $8.61 | $2.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $7.67 |
| AVG Volume (30 Days) | 158.5K | ★ 177.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,213,000.00 | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.69 | N/A |
| 52 Week Low | $4.07 | $1.76 |
| 52 Week High | $14.64 | $5.33 |
| Indicator | DMRC | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 71.47 | 34.89 |
| Support Level | $7.82 | $1.96 |
| Resistance Level | $8.93 | $2.37 |
| Average True Range (ATR) | 0.56 | 0.12 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 98.12 | 14.29 |
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.